The platform developed by Healthgen is an answer to the scientifically exciting and economically important issue of transgenic plants (and by extension other plant-based systems) as a viable alternative to blood product proteins or to recombinant proteins from other mostly fermentation-based platforms. The platform demonstrates that a plant-derived protein pharmaceutical is identical to an approved plasma-derived protein drug in clinical use and the company has established several platforms, including general protein expression, small peptide expression, and recombinant protein processing platforms. The company is also providing services of expressing products as required by the customers.
Its quality control system has been certified by Societe Generale de Surveillance S A for meeting the ISO 9001: 2008 requirements. With the scale production facilities built and managed according to the GMP requirement, all its products meet current required standards.

Healthgen Biotech has obtained total investment of $6 million and plans to raise an additional $7 million by 2012. In future, Healthgen will follow up the pre-clinical trial, clinical trial and approval of OsrHSA from the SFDA for human use. Simultaneously, the company will enhance the R&D activities to improve the technical platform and continue to develop more PMP products.